Hims & Hers Health (NYSE:HIMS) Upgraded at Zacks Research

Hims & Hers Health (NYSE:HIMS) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday,Zacks.com reports.

Several other equities analysts have also commented on HIMS. Barclays lowered their price target on shares of Hims & Hers Health from $48.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday. Morgan Stanley cut their price objective on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday. Deutsche Bank Aktiengesellschaft set a $31.00 target price on shares of Hims & Hers Health and gave the stock a “hold” rating in a report on Tuesday, February 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Finally, Leerink Partners reduced their price objective on shares of Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating for the company in a research note on Tuesday. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $32.27.

Hims & Hers Health Trading Down 1.3%

NYSE:HIMS opened at $15.61 on Wednesday. The company has a market cap of $3.55 billion, a PE ratio of 30.61, a P/E/G ratio of 3.38 and a beta of 2.43. The business’s 50 day moving average is $27.02 and its two-hundred day moving average is $39.43. The company has a quick ratio of 1.64, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. During the same quarter in the previous year, the firm earned $0.11 earnings per share. The firm’s revenue for the quarter was up 28.4% compared to the same quarter last year. On average, analysts predict that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health declared that its board has authorized a stock buyback plan on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 3% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In other Hims & Hers Health news, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the transaction, the insider owned 2,126 shares in the company, valued at approximately $78,045.46. This represents a 79.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the sale, the insider owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This represents a 53.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 82,963 shares of company stock worth $2,944,621 over the last ninety days. 13.71% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health in the 2nd quarter valued at $26,000. Quent Capital LLC acquired a new position in Hims & Hers Health during the 3rd quarter worth $28,000. Flagship Harbor Advisors LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the third quarter valued at about $28,000. Finally, Bogart Wealth LLC increased its position in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 632 shares during the period. Institutional investors own 63.52% of the company’s stock.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Management continues to emphasize growth and is pursuing a large international expansion via a planned acquisition of Eucalyptus, which could boost scale and addressable market outside the U.S. Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans
• Neutral Sentiment: Investor interest is elevated — unusually large options volume was reported, signaling higher speculative or hedging activity that can amplify moves in either direction. Hims & Hers Health Sees Unusually Large Options Volume (NYSE:HIMS)
• Neutral Sentiment: Comparative coverage (HIMS vs. AMWL) highlights differing telehealth strategies; useful for investors evaluating sector exposure but not an immediate catalyst. HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?
• Negative Sentiment: The SEC has opened an inquiry into Hims’ disclosures about compounded GLP‑1 (semaglutide) products, increasing regulatory risk and disclosure uncertainty. Hims & Hers Stock Faces Heavy Sell-Off Amid SEC Probe Into GLP-1 Disclosures
• Negative Sentiment: Novo Nordisk filed suit alleging patent infringement over compounded weight‑loss drugs; Hims withdrew its compounded semaglutide product—potential legal and liability exposure. Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans
• Negative Sentiment: The Law Offices of Frank R. Cruz announced an investor investigation into whether the board breached fiduciary duties related to these matters, which raises litigation risk and governance scrutiny. The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
• Negative Sentiment: Multiple analyst actions: Citigroup cut its price target to $13.25 and BTIG downgraded HIMS to Neutral; those notes prompted downgrades and contributed to heavy intraday selling. Citigroup Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $13.25 BTIG Research Downgrades Hims & Hers Health (NYSE:HIMS) to Neutral
• Negative Sentiment: Shares have hit new lows after the analyst activity and headlines; commentary also flagged potential near‑term pressure from a Super Bowl ad and changes to shipping cadence that could affect short‑term volumes. Hims & Hers Stock Stumbles – Cautions About Pressure Due To Super Bowl Ad, Change In Shipping Cadences
• Negative Sentiment: Overall coverage (TipRanks, Market commentary) highlights elevated reputation, partnership and liability risks from compounded‑drug scrutiny—factors that could weigh on sentiment until legal/regulatory clarity is reached. Regulatory Scrutiny of Compounded Drugs Puts Hims & Hers’ Growth, Partnerships, and Liability Risk in the Spotlight

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.